MPAL: Difference between revisions
From haematologyetc.co.uk
No edit summary |
No edit summary |
||
Line 11: | Line 11: | ||
</div></div></div> | </div></div></div> | ||
|- | |- | ||
|colspan="2" style = "font-size:90%; color:black; background:#ddeee1" |''' | |colspan="2" style = "font-size:90%; color:black; background:#ddeee1" |'''Marker option 1''' | ||
|- | |- | ||
|colspan="1" style = "font-size:90%; color:black;" |'''[[MPO|Myeloperoxidase (MPO)]]''' | |colspan="1" style = "font-size:90%; color:black;" |'''[[MPO|Myeloperoxidase (MPO)]]''' | ||
|colspan="1" style = "font-size:90%;"|This marker alone is sufficient to establish myeloid lineage provided it meets the intensity definition - intensity should be at least half of that of mature neutrophils in at least of proportion of cells. | |colspan="1" style = "font-size:90%;"|This marker alone is sufficient to establish myeloid lineage provided it meets the intensity definition - intensity should be at least half of that of mature neutrophils in at least of proportion of cells. | ||
|- | |- | ||
|colspan="2" style = "font-size:90%; color:black; background:#ddeee1" |''' | |colspan="2" style = "font-size:90%; color:black; background:#ddeee1" |'''marker option 2''' | ||
|- | |- | ||
|colspan="2" style = "font-size:90%;|If MPO does not meet criteria for myeloid lineage, then myeloid lineage may still be assigned through demonstration of monocytic lineage. This can be assigned by the detection of '''at least two''' of the following features: By flow cytometry: [[CD11c]], [[CD14]], [[CD64]]; by other approaches: '''raised lysozyme in serum or urine''' or '''non-specific esterase''' in malignant cells (enzyme cytochemistry) | |colspan="2" style = "font-size:90%;|If MPO does not meet criteria for myeloid lineage, then myeloid lineage may still be assigned through demonstration of monocytic lineage. This can be assigned by the detection of '''at least two''' of the following features: By flow cytometry: [[CD11c]], [[CD14]], [[CD64]]; by other approaches: '''raised lysozyme in serum or urine''' or '''non-specific esterase''' in malignant cells (enzyme cytochemistry) | ||
Line 34: | Line 34: | ||
</div></div></div> | </div></div></div> | ||
|- | |- | ||
|colspan="2" style = "font-size:90%; color:black; background:#ddeee1" |'''Marker | |colspan="2" style = "font-size:90%; color:black; background:#ddeee1" |'''Marker option 1''' | ||
|- | |- | ||
|colspan="1" style = "font-size:90%; color:black;"|'''Required''' [[CD19|Strong expression of CD19]] | |colspan="1" style = "font-size:90%; color:black;"|'''Required''' [[CD19|Strong expression of CD19]] | ||
Line 42: | Line 42: | ||
|colspan="1" style = "font-size:90%;"|If CD19 is strong then B-lineage can be assigned if there is '''at least ONE''' of these additional markers | |colspan="1" style = "font-size:90%;"|If CD19 is strong then B-lineage can be assigned if there is '''at least ONE''' of these additional markers | ||
|- | |- | ||
|colspan="2" style = "font-size:90%; color:black; background:#ddeee1" |'''Marker | |colspan="2" style = "font-size:90%; color:black; background:#ddeee1" |'''Marker option 2''' | ||
|- | |- | ||
|colspan="1" style = "font-size:90%; color:black;"|'''Required''' [[CD19|Weak expression of CD19]] | |colspan="1" style = "font-size:90%; color:black;"|'''Required''' [[CD19|Weak expression of CD19]] | ||
Line 86: | Line 86: | ||
</div></div></div> | </div></div></div> | ||
|- | |- | ||
|colspan="2" style = "font-size:90%; color:black; background:#ddeee1" |'''Marker | |colspan="2" style = "font-size:90%; color:black; background:#ddeee1" |'''Marker requirement 1''' | ||
|- | |- | ||
|colspan="2" style = "font-size:90%; color:black;"|'''Required''' No lineage assignment can be made for myeloid, B-lymphoid or T-lymphoid using the criteria above | |colspan="2" style = "font-size:90%; color:black;"|'''Required''' No lineage assignment can be made for myeloid, B-lymphoid or T-lymphoid using the criteria above | ||
|- | |- | ||
|colspan="2" style = "font-size:90%; color:black; background:#ddeee1" |'''Marker combination 2''' | |colspan="2" style = "font-size:90%; color:black; background:#ddeee1" |'''Marker combination 2''' |
Revision as of 15:19, 27 July 2023
Final lineage in MPAL requires integration of additional molecular features, so assigments made by flow should be regarded as "provisional" pending full molecular assessment.
.
Requirements to assign myeloid lineage in MPAL
| |
---|---|
Marker option 1 | |
Myeloperoxidase (MPO) | This marker alone is sufficient to establish myeloid lineage provided it meets the intensity definition - intensity should be at least half of that of mature neutrophils in at least of proportion of cells. |
marker option 2 | |
If MPO does not meet criteria for myeloid lineage, then myeloid lineage may still be assigned through demonstration of monocytic lineage. This can be assigned by the detection of at least two of the following features: By flow cytometry: CD11c, CD14, CD64; by other approaches: raised lysozyme in serum or urine or non-specific esterase in malignant cells (enzyme cytochemistry) |
.
Lineage assignments 2 - defining B-lymphoid lineage in MPAL
| |
---|---|
Marker option 1 | |
Required Strong expression of CD19 | To meet the definition of "strong" the expression intensity must exceed that of 50% of normal B lymphocytes |
In addition: CD10, CD22, or CD79a | If CD19 is strong then B-lineage can be assigned if there is at least ONE of these additional markers |
Marker option 2 | |
Required Weak expression of CD19 | To meet the definition of "weak" the expression intensity must be less than that of 50% of normal B lymphocytes |
In addition: CD10, CD22, or CD79a | If CD19 is strong then B-lineage can be assigned if there is at least TWO of these additional markers |
.
Lineage assignments 3 - defining T-lymphoid lineage in MPAL
| |
---|---|
Marker requirement | |
Either CD3 surface or cytoplasm (strong) | To meet the definition of "strong" the expression intensity must exceed that of 50% of normal T lymphocytes |
Or CD3 by immunocytochemistry (strong) | For immunohistochemistry it is important a non-zeta chain reagent is used |
.
Lineage assignments 4 - defining undifferentiated leukaemia
| |
---|---|
Marker requirement 1 | |
Required No lineage assignment can be made for myeloid, B-lymphoid or T-lymphoid using the criteria above | |
Marker combination 2 | |
Required Weak expression of CD19 | To meet the definition of "weak" the expression intensity must be less than that of 50% of normal B lymphocytes |
In addition: CD10, CD22, or CD79a | If CD19 is strong then B-lineage can be assigned if there is at least TWO of these additional markers |